The Pharma Data

MARCH 7, 2022

By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. PRC2 can be blocked with chemicals, but they are imprecise, affecting PRC2 function throughout the genome. it can be reawakened.

Protein 52

Protein Gene Genome Genomics 52

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

JANUARY 3, 2023

Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. cytokine-receptor disrupters).

DNA 52

DNA Protein Drugs RNA 52

Pharmaceutical Technology

JUNE 23, 2022

It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins. These viruses can develop rapid defences at the cellular level by orchestrating these layers, or folding mechanisms, in viral proteins so the key is to find a way to shut them down.”.

Drugs 130

Drugs Protein Genome Genomics 130

Drug Discovery World

MARCH 26, 2024

More importantly, it also highlighted that significant challenges remain in selecting the right therapies for the right patients despite the progress made through genomic testing and implementation of circulating tumour (ct) DNA analyses.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

MAY 2, 2023

Steve Wowk , VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. In an effort to defend themselves against viral infection, bacterial cells capture and copy DNA fragments of bacteriophages into their genome.

Genome 52

Genome Genomics Gene DNA 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. Its job is to carry coding information that is essential to the translation and processing of functional proteins.

RNA 52

RNA Protein Vaccination Vaccine 52

Drug Discovery World

MARCH 2, 2023

Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome. But the new findings answer a fundamental and longstanding question – how epigenetic proteins regulate the processes of transcription and gene expression, through which our genes are read and translated into proteins.

Gene Expression 52

Gene Expression Gene DNA RNA 52

Drug Discovery World

SEPTEMBER 27, 2023

Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy. Life experiences leave epigenetic footprints In recent decades, research has unveiled the impact of life experiences on DNA methylation.

DNA 115

DNA Genetics Gene Medicine 115

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg. parvovirus B19, Flaviviridae, Ebola, and Coronaviridae), DNA viruses (e.g.,

DNA 98

DNA Genome Genomics RNA 98

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98

DNA Drugs Antibody Engineer 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These systems include human and mouse cell lines, and even in vivo in live animals.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Drug Discovery World

DECEMBER 15, 2022

These platforms all induce double strand cuts in the chromosomal DNA that can be sealed by the cell, leading to a specific gene disruption, or resulting in a new target site for inserting DNA segments. Reduce/eliminate chromosomal disruptions caused by double-strand DNA breaks. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

APRIL 14, 2023

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. To do this, Nautilus will useits protein analysis platform to provide TGen with data on the proteins involved in DPIG.

Protein 52

Protein Genome Genomics DNA 52

Drug Discovery World

APRIL 17, 2024

DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA (regRNA) molecules control the expression of genes. JMB: Regulatory RNAs (or regRNAS) are molecules that directly control the expression of nearby protein-coding genes. DS: You describe your therapeutics as RNA Amplifiers. How do they work?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Drug Discovery World

APRIL 18, 2023

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data.

DNA 52

DNA Genome Genomics HR 52

Drug Discovery World

FEBRUARY 6, 2024

Scientific sessions Tuesday’s presentations spanned a range of topics, including functional genomics for target identification, next-generation proteomics, self-driving laboratories, the future of cell culture, and ‘lab on a particle’ technology.

Life Science 64

Life Science Genome Genomics RNA 64

XTalks

MAY 4, 2021

The tool targets the epigenome, the collection of DNA modifications in a cell such as methylation and post-translational histone modifications. These modifications regulate gene expression without changing the sequence or structure of DNA. DNA methylation occurs endogenously in all mammalian cells in response to various stimuli.

DNA 98

DNA Gene Gene Silencing Genome 98

Drug Discovery World

JANUARY 17, 2024

ctDNA is fragmented DNA released from dead or dying cancer cells, through the process of apoptosis or necrosis. ctDNA carries fragments of genomic information, whereas CTCs carry whole sequences, facilitating not only genomic, but transcriptomic and proteomic analysis. 21 In a recent publication, Silvestri et al.,

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

AUGUST 16, 2023

Additionally, patients whose cancer has spread but who have not yet received chemotherapy, and whose primary tumours have markers of faults in genes linked to DNA repair pathways, tend to respond better to carboplatin. “Our findings paint a complex picture – with many, dynamic factors driving how tumours respond to treatment.”

Genetics 52

Genetics Gene Hormones RNA 52

pharmaphorum

FEBRUARY 3, 2021

However, caveats surrounding the stochastic off-target outcomes of cleaving both strands of the DNA helix to elicit a gene modification remain a source of concern. Traditional CRISPR-Cas9 technology relies on generating a DSB in the DNA to facilitate a genetic modification. Base editing to get cell therapies on point.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. Alpine Immune Sciences has recently announced an augmentation in its R&D investment.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

MAY 4, 2021

The tool targets the epigenome, the collection of DNA modifications in a cell such as methylation and post-translational histone modifications. These modifications regulate gene expression without altering the sequence or structure of DNA. DNA methylation occurs endogenously in all mammalian cells in response to various stimuli.

DNA 52

DNA Gene Gene Silencing Genome 52

Drug Discovery World

JANUARY 21, 2024

It is enabling computational protein design for vaccine immunogen discovery, and high-throughput and high-definition assays for quicker and more comprehensive characterisation of vaccine candidates and vaccine-elicited immunity. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Protein 52

Protein Vaccination Vaccine Development 52

The Pharma Data

NOVEMBER 22, 2020

Cas-9 represents the Cas9 protein, an enzyme that cuts foreign DNA. “Then the RNA plus the protein [Cas9] will cut — like a pair of scissors — the DNA at that site, and ideally nowhere else.”. . Once the DNA has been cut, the cell’s natural repair mechanisms kick in. ” Source link. .

Gene Editing 52

Gene Editing DNA Genome Genomics 52

The Pharma Data

DECEMBER 3, 2020

The amount of DNA produced is much higher, and a positive test result can be viewed visually without the need for an additional analysis step,” the study reported. Sherlock Biosciences uses Cas13 to cut reporter RNA sequences after activation by guide RNA. Other techniques are primed to replace it.

RNA 52

RNA Protein DNA Antibody 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

OCTOBER 6, 2022

Jarret Glasscock , PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. . New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52

Drug Discovery World

JUNE 6, 2023

I think they are still just at the cusp of really understanding how we use the molecular degrader and how we optimise them towards something that is clinically relevant, rather than a research tool which shows we can degrade the protein and understand the pharmacology but isn’t necessarily endowed with all the right properties to be a drug.

Protein 52

Protein DNA RNA Research 52

XTalks

AUGUST 12, 2020

Studies have identified the presence of two types of HIV-infected CD4+ T cells: ‘Transcriptionally inactive’ cells that do not typically produce viral RNA or viral proteins. Transcriptionally active’ cells in which HIV RNA is actively transcribed to make copies of the virus (despite long-term ART).

RNA 52

RNA Protein DNA In-Vivo 52

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector. 2016/17 saw the emergence of this novel CRISPR-Cas9-based approach.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

AUGUST 10, 2022

To overcome this evasion tactic, the CAR protein was developed to recognise other markers on cancer cells. CAR is a fusion protein composed of an extracellular antibody fragment that recognises antigens and an intracellular domain that directs the T cell to the tumour. Identifying the right CAR T cell target.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

FEBRUARY 28, 2023

mRNA enables the delivery of a transiently expressed genetic molecule that is translated into a target protein using the machinery of the host cell. Finally, dosing and timing may be controlled simply by adjusting the amount of mRNA delivered to the cells, rather than relying on inducible systems that are integrated into the genome.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. At PhoreMost, we have been particularly excited about the emergence of targeted protein degradation (TPD) as a new therapeutic modality.

Research 52

Research Drugs Protein RNA 52